McPhersons (ASX:MCP) - Resigned CEO & Managing Director, Laurie McAllister
Resigned CEO & Managing Director, Laurie McAllister
Source: The CEO Magazine
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9
  • Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth
  • One of his highlights is the successful acquisition of Global Therapeutics in NSW
  • In the interim, Non-Executive Director Grant Peck will replace Laurie to aid in the transition to a more permanent holder
  • McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course
  • Company shares are down 6.8 per cent and are trading at $1.17

Laurie McAllister has resigned as CEO and Managing Director of McPherson’s (MCP), effective December 9.

Laurie has led the health and wellness company over the past four years and MCP says he leaves the company in a strong position for future growth.

One of his highlights is the successful acquisition of Global Therapeutics in Byron Bay, NSW.

Before joining McPherson’s, Laurie worked at Coca-Cola for 23 years, where he had a stint as the Chief Commercial & Marketing Officer for Japan.

Laurie will remain available for a short period of time to assist McPherson’s executive team if required.

In the interim, Non-Executive Director Grant Peck will replace Laurie, effective December 10. This will provide continuity and aid in the transition to a more permanent holder.

Grant has been a Non-Executive Director since December 2017 and is also a member and Chairman of McPherson’s Audit, Risk Management and Compliance Committee.

McPherson’s will now begin the steps to appoint a more permanent CEO and Managing Director and will provide further announcements in due course.

Company shares are down 6.8 per cent and are trading at $1.17 at 2:10 pm AEDT.

MCP by the numbers
More From The Market Online
Pancreatic cancer 3D illustration

Smallcap Radiopharm notches +12% jump on pancreatic cancer imaging win

Radiopharm Theranostics (ASX:RAD) has seen the safety profile of its pancreatic cancer imaging drug RAD 301…
Medical professional holding a tablet

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy…
AI image representing intellecutal property

Biome reaches intellectual property milestone in strain development program

Biome Australia Ltd has achieved an important milestone in development of a biome strain, preparing for…
Deal rejection concept

IDT Australia’s buyout offer from Mynd scrapped as latter leaves IDT hanging

IDT Australia (ASX:IDT) has confirmed its proposed takeover offer from a company called Myndbio for 15cps…